Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.

Laplaud DA, Casey R, Barbin L, Debouverie M, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Lubetzki C, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Magy L, Defer G, Guennoc AM, Maubeuge N, Labeyrie C, Patry I, Nifle C, Casez O, Michel L, Rollot F, Leray E, Vukusic S, Foucher Y; SFSEP and OFSEP groups.

Neurology. 2019 Aug 13;93(7):e635-e646. doi: 10.1212/WNL.0000000000007938. Epub 2019 Jul 12.

PMID:
31300547
2.

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.

Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D'Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Clerico M, Trojano M, Patti F, Vukusic S; PRIMS and POPARTMUS investigators.

Mult Scler. 2019 Apr;25(4):591-600. doi: 10.1177/1352458518763080. Epub 2018 Mar 20.

PMID:
31081475
3.

Dronabinol use in France between 2004 and 2017.

Lejczak S, Rousselot H, Di Patrizio P, Debouverie M.

Rev Neurol (Paris). 2019 May;175(5):298-304. doi: 10.1016/j.neurol.2018.07.011. Epub 2019 Apr 1.

PMID:
30948262
4.

High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis.

Gamraoui S, Mathey G, Debouverie M, Malaplate C, Anxionnat R, Guillemin F, Epstein J.

J Neurol. 2019 Apr;266(4):902-909. doi: 10.1007/s00415-019-09212-4. Epub 2019 Feb 1.

PMID:
30707357
5.

Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.

Vukusic S, Casey R, Rollot F, Brochet B, Pelletier J, Laplaud DA, De Sèze J, Cotton F, Moreau T, Stankoff B, Fontaine B, Guillemin F, Debouverie M, Clanet M; the OFSEP Investigators.

Mult Scler. 2018 Dec 13:1352458518815602. doi: 10.1177/1352458518815602. [Epub ahead of print]

PMID:
30541380
6.

Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study.

Chartier N, Epstein J, Soudant M, Dahan C, Michaud M, Pittion-Vouyovitch S, Guillemin F, Debouverie M, Mathey G.

Eur J Neurol. 2018 Dec;25(12):1439-1445. doi: 10.1111/ene.13748. Epub 2018 Aug 3.

PMID:
29996003
7.

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study.

Tourbah A, Gout O, Vighetto A, Deburghgraeve V, Pelletier J, Papeix C, Lebrun-Frenay C, Labauge P, Brassat D, Toosy A, Laplaud DA, Outteryck O, Moreau T, Debouverie M, Clavelou P, Heinzlef O, De Sèze J, Defer G, Sedel F, Arndt C.

CNS Drugs. 2018 Jul;32(7):661-672. doi: 10.1007/s40263-018-0528-2.

8.

Efficacy of rituximab in refractory RRMS.

Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, Carra-Dalliere C, Labauge P, Mathey G, Debouverie M, Papeix C, Maillart E, Lubetzki C, Bensa C, Gout O, Giannesini C, Stankoff B, Ciron J, Brassat D, Pelletier J, Rico Lamy A, Audoin B.

Mult Scler. 2019 May;25(6):828-836. doi: 10.1177/1352458518772748. Epub 2018 May 3.

PMID:
29722639
9.

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R; OFSEP and NOMADMUS Study Group.

Neurology. 2018 May 22;90(21):e1858-e1869. doi: 10.1212/WNL.0000000000005560. Epub 2018 Apr 25.

PMID:
29695592
10.

Classification and diagnostic criteria for demyelinating diseases of the central nervous system: Where do we stand today?

Mathey G, Michaud M, Pittion-Vouyovitch S, Debouverie M.

Rev Neurol (Paris). 2018 Jun;174(6):378-390. doi: 10.1016/j.neurol.2018.01.368. Epub 2018 Apr 16. Review.

PMID:
29673575
11.

Generational changes in multiple sclerosis phenotype in North African immigrants in France: A population-based observational study.

Nardin C, Latarche C, Soudant M, Dahan C, Michaud M, Pittion-Vouyovitch S, Guillemin F, Debouverie M, Mathey G.

PLoS One. 2018 Mar 27;13(3):e0194115. doi: 10.1371/journal.pone.0194115. eCollection 2018.

12.

Quantitative and qualitative normative dataset for intraepidermal nerve fibers using skin biopsy.

Collongues N, Samama B, Schmidt-Mutter C, Chamard-Witkowski L, Debouverie M, Chanson JB, Antal MC, Benardais K, de Seze J, Velten M, Boehm N.

PLoS One. 2018 Jan 25;13(1):e0191614. doi: 10.1371/journal.pone.0191614. eCollection 2018.

13.

Implementation and Evaluation of an Economic Model for Telestroke: Experience from Virtuall, France.

Riou-Comte N, Mione G, Humbertjean L, Brunner A, Vezain A, Lavandier K, Marchal S, Bracard S, Debouverie M, Richard S.

Front Neurol. 2017 Nov 20;8:613. doi: 10.3389/fneur.2017.00613. eCollection 2017.

14.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
15.

Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study.

Guillemin F, Baumann C, Epstein J, Kerschen P, Garot T, Mathey G, Debouverie M; LORSEP Group.

Neuroepidemiology. 2017;48(3-4):179-187. doi: 10.1159/000479516. Epub 2017 Aug 10.

PMID:
28793296
16.

Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.

Foulon S, Maura G, Dalichampt M, Alla F, Debouverie M, Moreau T, Weill A.

J Neurol. 2017 Jun;264(6):1185-1192. doi: 10.1007/s00415-017-8513-0. Epub 2017 May 17.

17.

Interactions between glioma and pregnancy: insight from a 52-case multicenter series.

Peeters S, Pagès M, Gauchotte G, Miquel C, Cartalat-Carel S, Guillamo JS, Capelle L, Delattre JY, Beauchesne P, Debouverie M, Fontaine D, Jouanneau E, Stecken J, Menei P, De Witte O, Colin P, Frappaz D, Lesimple T, Bauchet L, Lopes M, Bozec L, Moyal E, Deroulers C, Varlet P, Zanello M, Chretien F, Oppenheim C, Duffau H, Taillandier L, Pallud J.

J Neurosurg. 2018 Jan;128(1):3-13. doi: 10.3171/2016.10.JNS16710. Epub 2017 Mar 3.

PMID:
28298039
18.

Hereditary spastic paraplegia due to a novel mutation of the REEP1 gene: Case report and literature review.

Richard S, Lavie J, Banneau G, Voirand N, Lavandier K, Debouverie M.

Medicine (Baltimore). 2017 Jan;96(3):e5911. doi: 10.1097/MD.0000000000005911. Review.

19.

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.

Brochet B, Deloire MS, Perez P, Loock T, Baschet L, Debouverie M, Pittion S, Ouallet JC, Clavelou P, de Sèze J, Collongues N, Vermersch P, Zéphir H, Castelnovo G, Labauge P, Lebrun C, Cohen M, Ruet A; PROMESS study investigators.

PLoS One. 2017 Jan 3;12(1):e0168834. doi: 10.1371/journal.pone.0168834. eCollection 2017.

20.

Geographical Heterogeneity of Multiple Sclerosis Prevalence in France.

Pivot D, Debouverie M, Grzebyk M, Brassat D, Clanet M, Clavelou P, Confavreux C, Edan G, Leray E, Moreau T, Vukusic S, Hédelin G, Guillemin F.

PLoS One. 2016 Dec 9;11(12):e0167556. doi: 10.1371/journal.pone.0167556. eCollection 2016.

21.

Diagnostic performance of peroxiredoxin 1 to determine time-of-onset of acute cerebral infarction.

Richard S, Lapierre V, Girerd N, Bonnerot M, Burkhard PR, Lagerstedt L, Bracard S, Debouverie M, Turck N, Sanchez JC.

Sci Rep. 2016 Dec 6;6:38300. doi: 10.1038/srep38300.

22.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks.

Neurology. 2016 Dec 6;87(23):2491-2494. Epub 2016 Nov 4. No abstract available.

PMID:
27815407
23.

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.

Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, De Sèze J, Debouverie M, Gout O, Clavelou P, Defer G, Laplaud DA, Moreau T, Labauge P, Brochet B, Sedel F, Pelletier J; MS-SPI study group.

Mult Scler. 2016 Nov;22(13):1719-1731. Epub 2016 Sep 1.

24.

Simulation training for emergency teams to manage acute ischemic stroke by telemedicine.

Richard S, Mione G, Varoqui C, Vezain A, Brunner A, Bracard S, Debouverie M, Braun M.

Medicine (Baltimore). 2016 Jun;95(24):e3924. doi: 10.1097/MD.0000000000003924. Erratum in: Medicine (Baltimore). 2016 Aug 07;95(31):e5074.

25.

Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study.

Berna F, Blanc F, Lebrun C, Castelnovo G, Clerc C, Debouverie M, Jouvenoz D, Marcel-Viallet M, Zaenker C, Zephir H, Vidailhet P, De Sèze J.

Mult Scler Relat Disord. 2016 Mar;6:93-6. doi: 10.1016/j.msard.2016.02.004. Epub 2016 Feb 12.

PMID:
27063631
26.

Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.

Peyro Saint Paul L, Creveuil C, Heinzlef O, De Seze J, Vermersch P, Castelnovo G, Cabre P, Debouverie M, Brochet B, Dupuy B, Lebiez P, Sartori É, Clavelou P, Brassat D, Lebrun-Frenay C, Daplaud D, Pelletier J, Coman I, Hautecoeur P, Tourbah A, Defer G.

J Neurol Sci. 2016 Apr 15;363:69-76. doi: 10.1016/j.jns.2016.02.012. Epub 2016 Feb 6.

PMID:
27000224
27.

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.

Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, Pelletier J, Vermersch P, Edan G, Lebrun-Frenay C, Clavelou P, Thouvenot E, Camdessanché JP, Tourbah A, Stankoff B, Al Khedr A, Cabre P, Papeix C, Berger E, Heinzlef O, Debroucker T, Moreau T, Gout O, Bourre B, Créange A, Labauge P, Magy L, Defer G, Foucher Y, Laplaud DA; CFSEP and OFSEP groups.

Neurology. 2016 Feb 23;86(8):771-8. doi: 10.1212/WNL.0000000000002395. Epub 2016 Jan 29.

28.

E-selectin and vascular cell adhesion molecule-1 as biomarkers of 3-month outcome in cerebrovascular diseases.

Richard S, Lagerstedt L, Burkhard PR, Debouverie M, Turck N, Sanchez JC.

J Inflamm (Lond). 2015 Nov 4;12:61. doi: 10.1186/s12950-015-0106-z. eCollection 2015.

29.

[Is it always useful to perform lumbar puncture for the diagnosis of multiple sclerosis? Yes].

Debouverie M.

Rev Neurol (Paris). 2015 Sep;171(8-9):605-6. doi: 10.1016/j.neurol.2015.07.009. Epub 2015 Aug 31. French. No abstract available.

PMID:
26337481
30.

Pixantrone: a B-cell-depleting immunosuppressant for multiple sclerosis patients with active disease.

Gonsette R, Debouverie M, Sindic C, Ferré JC, Edan G.

Mult Scler. 2016 May;22(6):817-21. doi: 10.1177/1352458515601902. Epub 2015 Aug 18.

PMID:
26286699
31.

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Leray E, Vukusic S, Debouverie M, Clanet M, Brochet B, de Sèze J, Zéphir H, Defer G, Lebrun-Frenay C, Moreau T, Clavelou P, Pelletier J, Berger E, Cabre P, Camdessanché JP, Kalson-Ray S, Confavreux C, Edan G.

PLoS One. 2015 Jul 6;10(7):e0132033. doi: 10.1371/journal.pone.0132033. eCollection 2015.

32.

No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients.

Becker M, Latarche C, Roman E, Debouverie M, Malaplate-Armand C, Guillemin F.

BMC Neurol. 2015 May 13;15:79. doi: 10.1186/s12883-015-0330-4.

33.

Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.

Siri A, Carra-Dalliere C, Ayrignac X, Pelletier J, Audoin B, Pittion-Vouyovitch S, Debouverie M, Lionnet C, Viala F, Sablot D, Brassat D, Ouallet JC, Ruet A, Brochet B, Taillandier L, Bauchet L, Derache N, Defer G, Cabre P, de Seze J, Lebrun Frenay C, Cohen M, Labauge P.

J Neurol. 2015 Jul;262(7):1637-45. doi: 10.1007/s00415-015-7758-8. Epub 2015 May 1.

PMID:
25929666
34.

Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients.

Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, Denier C, Aubourg P, Bellesme C, Castelnovo G, Pelletier J, Audoin B, Kaphan E, de Seze J, Collongues N, Blanc F, Chanson JB, Magnin E, Berger E, Vukusic S, Durand-Dubief F, Camdessanche JP, Cohen M, Lebrun-Frenay C, Brassat D, Clanet M, Vermersch P, Zephir H, Outteryck O, Wiertlewski S, Laplaud DA, Ouallet JC, Brochet B, Goizet C, Debouverie M, Pittion S, Edan G, Deburghgraeve V, Le Page E, Verny C, Amati-Bonneau P, Bonneau D, Hannequin D, Guyant-Maréchal L, Derache N, Defer GL, Moreau T, Giroud M, Guennoc AM, Clavelou P, Taithe F, Mathis S, Neau JP, Magy L, Devoize JL, Bataillard M, Masliah-Planchon J, Dorboz I, Tournier-Lasserve E, Levade T, Boespflug Tanguy O, Labauge P.

Brain. 2015 Feb;138(Pt 2):284-92. doi: 10.1093/brain/awu353. Epub 2014 Dec 19.

PMID:
25527826
35.

Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis.

Manceau P, Latarche C, Pittion S, Edan G, de Sèze J, Massart C, Debouverie M.

BMC Neurol. 2014 Nov 30;14:215. doi: 10.1186/s12883-014-0215-y.

36.

[Neurologic diseases in a rural tropical area: experience at a primary health care center in the Boeny region of Madagascar].

Gaud S, Sauvée M, Debouverie M.

Med Sante Trop. 2014 Jul-Sep;24(3):312-6. doi: 10.1684/mst.2014.0370. French.

37.

[Impact of training conferences on medical student's performance for the French National Ranking Examination in Lorraine University. The ETIMCEL experimental study].

Agrinier N, Bannay A, Santini J, Braun M, Angioi K, Debouverie M, Zuily S; le Groupe ETIMCEL.

Rev Med Interne. 2015 Feb;36(2):78-88. doi: 10.1016/j.revmed.2014.04.010. Epub 2014 Aug 7. French.

PMID:
25109445
38.

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C; Club Francophone de la Sclérose en Plaques Investigators.

JAMA Neurol. 2014 Apr;71(4):436-41. doi: 10.1001/jamaneurol.2013.6240.

PMID:
24566807
39.

Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease.

Zéphir H, Gower-Rousseau C, Salleron J, Simon O, Debouverie M, Le Page E, Bouhnik Y, Lebrun-Frenay C, Papeix C, Vigneron B, Allez M, Prin L, Cosnes J, Vermersch P, Colombel JF; CFSEP, GETAID and EPIMAD Groups.

Mult Scler. 2014 Jul;20(8):1135-9. doi: 10.1177/1352458513515081. Epub 2013 Dec 10.

PMID:
24326672
40.

Clinical allergy. Managing generalized interferon-induced eruptions and the effectiveness of desensitization.

Poreaux C, Bronowicki JP, Debouverie M, Schmutz JL, Waton J, Barbaud A.

Clin Exp Allergy. 2014;44(5):756-64. doi: 10.1111/cea.12217.

PMID:
24128045
41.

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.

Outteryck O, Ongagna JC, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet JC, Berger E, Cohen M, Pittion S, Laplaud D, Wiertlewski S, Cabre P, Pelletier J, Rico A, Defer G, Derache N, Camu W, Thouvenot E, Moreau T, Fromont A, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Casez O, Hautecoeur P, Papeix C, Lubetzki C, Fontaine B, Couturier N, Bohossian N, Clanet M, Vermersch P, de Sèze J, Brassat D; BIONAT Network,; CFSEP.

Eur J Neurol. 2014;21(1):40-8. doi: 10.1111/ene.12204. Epub 2013 Jun 12.

PMID:
23895407
42.

Cognitive impairment among different clinical courses of multiple sclerosis.

Brissart H, Morele E, Baumann C, Perf ML, Leininger M, Taillemite L, Dillier C, Pittion S, Spitz E, Debouverie M.

Neurol Res. 2013 Oct;35(8):867-72. doi: 10.1179/1743132813Y.0000000232. Epub 2013 Jun 19.

PMID:
23816638
43.

Item reduction based on rigorous methodological guidelines is necessary to maintain validity when shortening composite measurement scales.

Goetz C, Coste J, Lemetayer F, Rat AC, Montel S, Recchia S, Debouverie M, Pouchot J, Spitz E, Guillemin F.

J Clin Epidemiol. 2013 Jul;66(7):710-8. doi: 10.1016/j.jclinepi.2012.12.015. Epub 2013 Apr 6. Review.

PMID:
23566375
44.

Cognitive rehabilitation in multiple sclerosis.

Brissart H, Leroy M, Morele E, Baumann C, Spitz E, Debouverie M.

Neurocase. 2013;19(6):553-65. doi: 10.1080/13554794.2012.701644. Epub 2012 Aug 1.

PMID:
22853712
45.

Paroxysmal hypothermia in two patients with multiple sclerosis.

Darlix A, Mathey G, Sauvée M, Braun M, Debouverie M.

Eur Neurol. 2012;67(5):268-71. doi: 10.1159/000331637. Epub 2012 Mar 30.

PMID:
22472481
46.

Estimating the prevalence and incidence of multiple sclerosis in the Lorraine region, France, by the capture-recapture method.

El Adssi H, Debouverie M, Guillemin F; LORSEP Group.

Mult Scler. 2012 Sep;18(9):1244-50. Epub 2012 Feb 21.

PMID:
22354740
47.

Verbal episodic memory in 426 multiple sclerosis patients: impairment in encoding, retrieval or both?

Brissart H, Morele E, Baumann C, Debouverie M.

Neurol Sci. 2012 Oct;33(5):1117-23. doi: 10.1007/s10072-011-0915-7. Epub 2012 Jan 13.

PMID:
22240715
48.

[Hypothalamic involvement in multiple sclerosis].

Darlix A, Mathey G, Monin ML, Sauvée M, Braun M, Schaff JL, Debouverie M.

Rev Neurol (Paris). 2012 May;168(5):434-43. doi: 10.1016/j.neurol.2011.09.004. Epub 2011 Dec 1. Review. French.

PMID:
22136879
49.

[Working memory in multiple sclerosis: a review].

Brissart H, Leininger M, Le Perf M, Taillemite L, Morele E, Debouverie M.

Rev Neurol (Paris). 2012 Jan;168(1):15-27. doi: 10.1016/j.neurol.2011.05.005. Epub 2011 Oct 29. Review. French.

PMID:
22041825
50.

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.

International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D'hooghe MB, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppä V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Rückert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sørensen PS, Søndergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvänen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A.

Nature. 2011 Aug 10;476(7359):214-9. doi: 10.1038/nature10251.

Supplemental Content

Loading ...
Support Center